MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
MannKind (Nasdaq: MNKD) announced CEO Michael Castagna, PharmD, will present business updates at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 11:20 a.m. ET.
A webcast link will be available on the company website and recorded versions will be posted for approximately 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – MNKD
In the Feb 19 session, MNKD gained 1.65%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 09 | Pediatric trial start | Positive | +2.3% | First patient enrolled in INHALE-1ST pediatric Afrezza study for T1D. |
| Jan 26 | Label update approval | Positive | +2.2% | FDA approved updated Afrezza label with dose conversion guidance. |
| Jan 08 | Business outlook update | Positive | +2.7% | Business updates highlighting >$100M Q4 revenue and 2026 growth drivers. |
| Dec 23 | FUROSCIX updates | Positive | -1.0% | FUROSCIX pediatric approval and new patents extending protection to 2040. |
| Dec 01 | sNDA acceptance | Positive | +1.5% | FDA accepted FUROSCIX ReadyFlow sNDA with July 26, 2026 PDUFA date. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company-specific news and regulatory milestones have generally seen positive price reactions, with one notable divergence on favorable FUROSCIX updates.
Over the last few months, MannKind reported several clinical and regulatory milestones: first patient enrollment in the INHALE-1ST pediatric Afrezza study, FDA approval of an updated Afrezza label on Jan 26, 2026, broader business and 2026 growth-driver updates, FUROSCIX pediatric and IP expansions, and FDA acceptance of the FUROSCIX ReadyFlow sNDA with a Jul 26, 2026 PDUFA date. Most of these announcements were followed by modestly positive 24-hour price moves, suggesting constructive market reception to recent progress.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced Chief Executive Officer Michael Castagna, PharmD is scheduled to present and share business updates during the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 11:20 a.m. ET
A link to the webcast of the presentation will be available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-presentations. Recorded versions will also be available on the website for approximately 90 days following the conference.
About MannKind
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.
Learn more at mannkindcorp.com.
Contacts: Investor Relations Kate Miranda (617) 921-5461 Email: ir@mnkd.com Media Relations Christie Iacangelo (818) 292-3500 Email: media@mnkd.com